The relationship will unite Sixfold’s state-of-the-art technology with Pharmidex’s leading expertise in drug discovery translation to obtain preclinical data required to further develop its therapeutic delivery system, MergoⓇ.

The collaboration, funded by the Sustainable Innovation Fund from Innovate UK, will also focus on enhancing Sixfold’s oligonucleotide manufacturing capabilities, scalably and sustainably. Partnering with Pharmidex for iterative preclinical experiments will accelerate Sixfold’s candidate development cycle.

Dr Ioanna Mylonaki, Sixfold Bioscience’s Head of Preclinical R&D, commented:

“We look forward to working with a reliable partner such as Pharmidex, to develop sustainable screening methods for our RNA delivery platform technology and bring therapies from bench to the patient bedside.”

Pharmidex’s Head of Oncology, Dr Christopher Ireson, commented:

“Pharmidex is delighted to collaborate with Sixfold within the remit of this exciting project, enabling the development of existing expertise within this therapeutic area and ultimately supporting the delivery of novel therapeutics to patients in areas of high unmet clinical need”.

Sixfold Bioscience Ltd.

Sixfold Bioscience is a venture-backed preclinical-stage biotechnology company based at the Innovation and Translation Hub in White City, London. Sixfold develops nucleic acid-based drug delivery systems, with a current focus on short interfering RNA for gene silencing and messenger RNA for gene expression. For more information, visit: https://www.sixfold.bio

Pharmidex

Pharmidex is a contract research organisation (CRO) that provides translational solutions using its world renowned expertise in CNS/oncology/respiratory, DMPK, drug discovery and ADMET/pharmacokinetics. Founded in the UK in 2002, Pharmidex operates in state-of-the-art facilities in London and Hatfield to provide high-quality bespoke experimental data to support drug discovery and development. For more information, visit: https://www.pharmidex.com